Abstract
Understanding the presence and durability of antibodies against SARS-CoV-2 in the airways is required to provide insights on the ability of individuals to neutralize the virus locally and prevent viral spread. Here, we longitudinally assessed both systemic and airway immune responses upon SARS-CoV-2 infection in a clinically well-characterized cohort of 147 infected individuals representing the full spectrum of COVID-19 severity; from asymptomatic infection to fatal disease. In addition, we evaluated how SARS-CoV-2 vaccination influenced the antibody responses in a subset of these individuals during convalescence. Not only systemic but also airway antibody responses correlated with the degree of disease severity with increasing levels in patients with mild, moderate and severe disease, respectively. However, while systemic IgG levels were durable for up to 8 months, airway IgG and IgA had declined significantly within 3 months. In contrast, antigen-specific memory B cells were well maintained and comparable across disease severity. After vaccination, there was an increase in both systemic and airway antibodies, in particular IgG, often exceeding the levels found during acute disease. In contrast to plasma, airway antibody levels were significantly elevated after the boost vaccination, highlighting the importance of prime and boost vaccination also for previously infected individuals to obtain optimal mucosal protection.
Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection that causes coronavirus disease 2019 (COVID-19) presents with a wide range of disease severity from asymptomatic to fatal (1, 2). Individuals of advanced age and/or those with comorbidities are overrepresented among patients who develop severe disease (3). However, the majority of SARS-CoV-2 infected individuals experience asymptomatic infection or only mild disease (4).
Systemic antibodies against the SARS-CoV-2 nucleocapsid (N) and the viral surface glycoprotein spike (S) as well as against the receptor binding domain (RBD) (5, 6) of the S protein have been studied extensively (7-11). Responses against the internal N protein are often readily detectable but their contribution to protection and control of disease is not clear (8, 10). In contrast, antibody responses against S and, in particular, against the RBD result in virus neutralization (12). Responses against the RBD are thus likely necessary for protection from re-infection or prevention of symptomatic disease. However, the presence and durability of antibodies during COVID-19 in the airways is still not well understood.
The respiratory tract is the initial site of viral infection and replication. The availability of antibodies at this site could therefore determine the ability to neutralize the virus locally in case of (re-) exposure and prevent viral spread. Generally, antibodies present in the circulation and at local sites are the result of secretion from short-lived plasmablasts and/or terminally differentiated plasma cells in the bone marrow or mucosal sites (13). However, the response to a secondary infection once antibody titers have waned below protective levels mostly relies on the presence of resting antigen-specific memory B cells that are rapidly activated upon antigen re-exposure (13). Whether vaccination against SARS-CoV-2 also elicits systemic antibody responses in addition to local antibodies in the airways of individuals who recovered from COVID-19, and via which mechanism, is currently unknown.
In this study we present data from a cohort of patients that we have followed since mid-March 2020, which was the start of the pandemic in Sweden. We show longitudinal data on virus-specific systemic and airway antibody and B cell memory responses generated in this clinically well-characterized cohort of individuals with SARS-CoV-2 infection (n=147) ranging from asymptomatic SARS-CoV-2 infection to fatal COVID-19 disease. In addition, we show how subsequent SARS-CoV-2 vaccination during the convalescent phase significantly boosts not only the systemic but also airway antibody responses.
Results
Patient enrollment, assessment of disease severity and timeline
Individuals were sampled longitudinally in blood and airways during acute infection/symptomatic disease and during convalescence (median 3 and 8 months from symptom onset). Donor-matched plasma, peripheral blood mononuclear cells (PBMC), nostril swabs (NSW) and nasopharyngeal aspirates (NPA) were collected from all patients across disease severities whereas endotracheal aspirates (ETA) were only collected from intubated patients receiving intensive care (Figure 1). Disease severity was assessed daily, using a seven-point scale derived from the respiratory domain of the sequential organ failure assessment (SOFA) score (14, 15), with additional levels for non-admitted and fatal cases (Table 1). Patients were grouped based on peak disease severity, which may differ from disease severity at time of sampling (Table 1 and Figure 1B). In addition, pre-pandemic healthy controls (PPHC) (n=30) as well as individuals with influenza-like symptoms, and possible SARS-CoV-2 exposure, but with negative diagnostic PCR results (PCR-) (n=9) were sampled in the same way and included as controls. Generally, severe patients were sampled later after symptom onset as compared with individuals with mild disease resulting in a large time frame of study inclusion with respect to symptom onset (Table 1 and Figure 1B) (16). For simplicity, the sampling period/study inclusion during ongoing infection and hospitalization (for those hospitalized) is referred to as the “acute” phase. Samples collected at the first follow-up visit during convalescence (range 46-168 days from symptom onset; median 108 days) are referred to as the “3 months” timepoint whereas those collected at the second follow-up visit (range 187-344 days; median 245 days) are referred to as the “8 months” timepoint. Time of the first convalescent follow-up sampling from acute sampling ranged 33-159 days; median 90 days (Table 1).
Clinical characterization of the SARS-CoV-2 infected cohort
(A) Overview of study cohort and controls, timeline of longitudinal sampling, hospital admission/discharge, level of care and outcome for each patient. Patients are group based on peak disease severity (PDS); mild (PDS 1 and 2), moderate (PDS 3 and 4), severe (PDS 5 and 6) and fatal (PDS 7). Individual inclusion sample for each patient is color-coded based on disease severity at the time of sampling. (B) Overview of the anatomical compartments analyzed, and the measurements performed.
Plasma IgG and IgA responses to N, S and RBD across COVID-19 severity during acute disease and after recovery
We first assessed systemic IgG and IgA responses against N, S and RBD at the time of study inclusion that ranged between 0-54 days from onset of symptoms; median 16 days for the whole cohort (Table 1). Both IgG and IgA levels against all viral proteins followed the degree of disease severity with increasing levels in patients with mild, moderate and severe disease respectively (Figure 2A). In line with previous reports, IgG against N were the most elevated in patients who had severe disease or a fatal outcome (8, 10). The degree of disease severity also associated with the levels of systemic inflammation as indicated by the levels of C-reactive protein (CRP) in blood and by the neutrophil-lymphocyte ratio (NLR) (Figure 2B). Interestingly, the levels of neutrophils also specifically associated with disease severity (Figure 2D) and with all of the systemic antibody responses during acute disease (Figure 2D and Supplementary figure 1). The levels of IgG during acute disease, and to a lower extent IgA, against all tested antigens, exhibited a positive correlation with the days from onset of symptoms (Supplementary figure 2A). This difference in antibody titers over time might be slightly accentuated by the fact that in our cohort the patients with moderate/severe disease, and even fatal outcome, for whom we initially observed low IgG titers against RBD, had an early study inclusion (on average 13 days from onset of symptoms). In fact, these patients showed significantly higher titers later during the acute phase (on average 19 days) (Supplementary figure 2B-C). Nonetheless, patients with mild disease displayed lower levels of plasma IgG against RBD as compared with more severe patients, also when samples were taken after similar duration of symptoms (Supplementary figure 2D). After 3 months from symptom onset, the IgG levels remained high in the plasma of patients recovering from moderate and severe disease, while the levels had further increased in the individuals who had a mild disease (Figure 3A). However, despite this increase over time, the antibody levels in mild patients never reached the levels observed for moderate and severe patients or for those who had a fatal outcome (Figure 3 and Supplementary figure 3A).
(A) Plasma IgG and IgA responses against N, S and RBD are shown together with the levels of (B) C-reactive protein and the neutrophil-lymphocyte ratio as a measure of systemic inflammation and with (C) the levels of lymphocytes, monocytes and neutrophils. Black lines indicate medians. Differences were assessed using Kruskal -Wallis with Dunn’s multiple comparisons test and considered statistically significant at p<0.05. ** p<0.01, *** p<0.001, **** p<0.0001. The dashed lines indicate the normal thresholds or range values. (D) Correlation matrix summarizing the interrelationship observed between the clinical parameters, inflammation markers, blood corpuscles and data from systemic antibody levels measured during acute disease as indicated. The P and R values (Spearman) are shown separately in the mirrored halves of the matrix and have been color-coded as indicated.
(A) Individual levels of plasma IgG and IgA (from left to right) in SARS-CoV-2 infected individuals with different peak disease severity (PDS). Black lines indicate medians and dotted lines indicate the average background level from pre-pandemic healthy controls. Mann-Whitney U was used to compare the groups and considered statistically significant at p<0.05. ** p<0.01, *** p<0.001, **** p<0.0001. (B) Compiled patient-matched longitudinal data from acute, 3-month- 8-month follow-ups are shown for the levels of plasma IgG and plasma IgA against RBD. For each chart, the black dotted pattern refers to the median value whereas the grey lines connect data points from the same individuals. The number in each graph indicates the slope of the line connecting the median OD values at 3- 8-months sampling as an estimate of the antibody decay. The asterisks indicate the statistical significance, calculated as per in Figure 3A.
The IgG levels had significantly waned from 3 to 8 months in patients who recovered from moderate and severe disease, but the decline was smaller in patients who experienced a mild disease (Figure 3B and Supplementary figure 3). In contrast to IgG, IgA levels from the acute phase, against all antigens, waned substantially in most patients already after 3 months (Figure 3 and Supplementary figure 3). Antibody titers during acute disease correlated with peak disease severity as well as with disease severity at time of sampling (Supplementary figure 4). The correlation between antibody titers and peak disease severity was maintained also when analyzing the antibodies at the 3- and 8-month follow-up visits (Supplementary figure 4) as also observed in another study (17).
Levels of IgG and IgA to RBD in (A) nostrils swabs (NSW) and (B) nasopharyngeal aspirates (NPA). The black lines indicate median values. Mann-Whitney U was used to compare the group and considered statistically significant at p<0.05. *p<0.05 ** p<0.01, *** p<0.001, **** p<0.0001. (C) Heat map generated grouping patients according to PDS showing acute and convalescent IgG and IgA titers against N, S and RBD (plasma) and RBC (NSW, NPA and ETA) for each patient. The heat map also includes data from PPHC and PCR-individuals (indicated with PDS 0). Missing data and not available samples are shown in black. (D) Comparison of the levels of RBD IgG/A in patient-matched NSW, NPA, endotracheal aspirates (ETA) and plasma collected at the same time point. (E) Spearman correlation for NPA versus plasma immunoglobulins against the RBD during acute disease. The black lines connect data points from the same individuals. Wilcoxon test was used to compare the groups separately and considered statistically significant at p<0.05. **** p<0.0001. In A) the line overlaps with not detected (ND) for IgG levels.
Airway IgG and IgA responses and assessment of B cell frequencies in the respiratory tract
We next measured the levels of IgG and IgA in the upper and lower airways and compared with levels in plasma at matched time points. Due to limited respiratory sample volumes, we focused our analyses on IgG and IgA responses against the RBD since these responses are most critical for virus neutralization. We found that RBD-specific antibodies could be detected in nasal swabs (NSW) (Figure 4A) and nasopharyngeal aspirates (NPA) (Figure 4B) during the acute phase across all disease severities (Figure 4A, B and C). In agreement with our observations in plasma, antibody levels in the upper respiratory tract were higher in patients with moderate or severe disease as compared with individuals with mild disease. Both IgG and IgA levels had declined significantly already after 3 months, with IgG declining to almost undetectable levels (Figure 4A- C). RBD antibody levels during acute infection were on average higher in NPA compared to NSW for both IgG and IgA across disease severity (Figure 4A- C) suggesting that antibody titers may increase not only with disease severity but also with sampling at different depths of the upper airways. To address this, we compared donor-matched NSW (peripheral nostril), NPA (upper airway) and ETA (trachea) collected at the same time point during acute disease from intubated patients from whom we had both peripheral, upper and lower airway samples. Interestingly, we still found significantly higher levels of IgA against the RBD in NPA as compared with NSW and ETA (Figure 4D).
Furthermore, nasopharyngeal antibody levels (both IgG and IgA) showed a strong correlation with plasma antibody responses (Figure 4E). We also assessed the presence of B cells in the respiratory tract of COVID-19 patients by analyzing the lymphocytes that could be retrieved from NPA and ETA as compared with NPA from three healthy controls (HC). Despite generally obtaining a significantly lower cell yield from NPA as compared with ETA, lymphocyte frequencies did not differ in NPA and ETA from COVID-19 patients but both were lower as compared with NPA from HC. Instead, the proportion of B cells in NPA was higher as compared with ETA in COVID-19 patients and similar to NPA from HC (Figure 5A-B).
(A) Representative example with gating strategy for the identification of lymphocytes (identified as negative for CD14/16/123/66) and of total B cells (CD3-CD19+) in respiratory NPA and ETA samples. (B) Levels of lymphocytes and of total B cells in NPA and ETA in a subset of patients alongside with NPA from healthy controls. Mann-Whitney test was used to compare the groups and considered statistically significant at p<0.05. ** p<0.01. (C) Representative examples with gating strategy of SARS-Cov-2 S-specific memory B cells from one pre-pandemic healthy control, 3-month follow-up samples from one SARS-CoV-2 PCR-individual and one mild and one moderate/severe COVID-19 patient. Further characterization of S-positive memory B cells on RBD binding and B cell isotype (IgG+ or IgA+ assumed to correspond to IgD-IgM-IgG-B cells). (D) Bar charts show the cumulative proportion (frequency) of Spike (blue) and RBD (yellow) specific memory B cell as well as the proportion of IgG (green) vs. IgA (red) isotypes among the Spike specific memory B cells in longitudinal samples from mild (n=6) and moderate/severe (n=8) COVID-19 patients. (E) Frequencies of S-specific memory B cells in matched acute (filled) and 3-month follow-up (filled with black lining) PBMCs in relation to days in the subset of individuals analyzed color-coded according to PDS. Dotted lines on indicate the average background staining from PCR- PPHC. (F) Levels of circulating Spike+ switched memory B cells during acute disease and convalesce in the subset of patients analyzed, as well as PPHC, color-coded according to PDS. Circles with black lining refer to data during the convalescent phase. Black triangles symbolize the PPHC. Differences were assessed using Kruskal -Wallis with Dunn’s multiple comparisons test and considered statistically significant at p<0.05. ** p<0.01.
Expansion of SARS-CoV-2-specific memory B cells
As mentioned above, the virus-specific B cell memory pool will be essential to remount a rapid antibody response in the case of re-exposure. To assess the establishment of antigen-specific memory B cells, donor-matched PBMC from acute disease and convalescence were analyzed side-by-side using fluorescently labelled S and RBD probes (18-20). Patients with moderate/severe disease showed the presence of Ig-switched memory B cells specific to S in the acute phase and the memory B cell pool had further expanded after 3 months (ranging from 0.009 to 1.35%; mean 0.42% during convalescence) (Figure 5C-F). Individuals with mild disease showed lower frequencies of S-specific memory B cells during acute disease than the patients with moderate/severe disease. In fact, the frequencies of S-specific memory B cells in the mild patients during the acute phase were not different from those observed in the PCR-individuals or in the PPHC (Figure 5C and E). However, the frequencies of S-specific memory B cells had substantially increased in the mild patients after 3 months (ranging from 0.17% to 0.64%; mean 0.35% during convalescence) and were comparable to frequencies among severe patients. In addition, the levels were well maintained between 3 and 8 months in all groups (Figure 5E and F). Further phenotyping of the S-specific memory B cells indicated that the majority of these cells may be specific for epitopes on S outside of the RBD (Figure 5D). S-specific memory B cells in the circulation were predominantly IgG+, rather than IgA+ (Figure 5D).
The effect of vaccination on systemic and airway antibody levels
We finally evaluated the influence of SARS-CoV-2 vaccination on the systemic and airway antibody responses (Figure 6A). A subset of 12 individuals, 2 that recovered from mild, 4 from moderate and 6 from severe COVID-19 one year earlier, were sampled after receiving their scheduled vaccination (range 270-358 days; median 326 days from symptom onset) (Table 2). Donor-matched plasma, NSW and NPA were collected at different timepoints after prime (7-16 days) from 10 patients and after boost (7-28 days) from 7 patients and analyzed for the presence of IgG and IgA against RBD. Antibodies against N were also measured in plasma as a negative control as the vaccines used were based on the S protein. After vaccination, all individuals demonstrated a significant increase of both plasma IgG and IgA against the RBD (Figure 6B and Supplementary figure 5) but, as expected, not against N (Figure 6B). The plasma antibody levels, especially IgG, to RBD further increased from prime to boost vaccination in the majority of individuals analyzed. However, due to the low numbers of individuals (n=5) who had this sample set available, this did not reach statistical significance (p=0.06). While the IgG levels to RBD after boost vaccination exceeded the levels detected during the acute phase, the IgA levels were equally high (Figure 6C). The airway IgG levels to RBD also showed a noticeable increase after the boost vaccination in particular. In fact, the IgG levels in the airway samples, both nasal swabs and NPA, were in most individuals significantly higher after boost vaccination than they were in the acute stage of the disease (Figure 6C). In contrast, this was not noted for IgA levels to RBD.
Peak disease severity, age, gender and longitudinal sampling timeline of patients vaccinated against SARS-CoV-2.
(A) Overview of vaccinated patients with respect with peak disease severity during COVID-19 and sampling timeline after prime and boost. The anatomical compartments analyzed and the measurements performed are also shown. Compiled patient-matched longitudinal data from acute, 3-month- 8-month follow-ups are shown together with data from after prime and after boost for (B) the levels of IgG and IgA against N and RNB for plasma and (C) against RBD for NSW and NPA. The grey lines connect data points from the same individuals. Data are color-coded according to peak disease severity during COVID-19 and differences were assessed using Kruskal -Wallis with Dunn’s multiple comparisons test and considered statistically significant at p<0.05. ** p<0.01, *** p<0.001, **** p<0.0001.
Discussion
By now, it is well documented that higher systemic antibody levels are generated in severe as compared with mild COVID-19 (7-11, 21-23). In contrast, the presence and durability of antibodies against SARS-CoV-2 in the airways is much less understood. Nor is it known if and how respiratory antibody levels are influenced by SARS-CoV-2 vaccination in humans. In this study, we performed longitudinal analyses of systemic and upper and lower airway antibody responses in a clinically well-characterized and relatively large cohort of individuals with SARS-CoV-2 infection representing the full spectrum of COVID-19 severity ranging from asymptomatic infection to fatal disease. Matched analyses in blood and in the airways enabled us not only to address the magnitude and durability of systemic antibodies to SARS-CoV-2 but also to gain insights into the prospects of protective capacity locally in the mucosa at virus re-entry. This is one key aspect still largely unknown yet critical for our understanding of immunity to and protection from SARS-CoV-2. Furthermore, we studied how the systemic versus airway antibody levels were affected by vaccination. Collectively, this data will contribute to a better understanding of long-term protective effects and whether vaccination is important to boost the capacity of virus neutralization in the airways and thus reducing re-infection and virus spread.
Airway mucus along the respiratory tract is thought to serve as a barrier that can trap respiratory viruses via virus glycoprotein-mucin interactions (24). However, it has been shown that local immobilization of respiratory viruses such as influenza viruses in the airways mostly occurs by binding with virus-specific antibodies present in the mucus (25). As the respiratory tract is the initial site of viral infection and replication, the levels of IgG and IgA against the RBD in the upper and lower airways are likely critical for SARS-CoV-2 neutralization and could therefore help predict the ability of individuals to neutralize the virus locally in case of re-exposure. Low but detectable levels of antibodies to SARS-CoV-2 have previously been reported in saliva during convalescence (26). In our study we found that IgG and IgA against the RBD can be readily detected in the upper and lower airway during acute disease and that such levels correlated with the systemic response at the same time point and also followed disease severity. However, for all the patients across disease severities, airway antibodies waned to low levels much faster than those in plasma during convalescence. Whether these low antibody levels observed at respiratory sites will be sufficient for preventing virus re-entry or for protection is not known. The correlation between systemic and airway antibody levels during acute disease raises questions on whether the low levels of antibodies in the airways during convalescence are due to decreased antibody generation locally at mucosal sites or are rather caused by decreased dissemination from the periphery once systemic antibody levels start to wane. Antibodies in the upper respiratory tract have been shown to be dominated by secretory IgA which are mostly produced by plasma cells in the lamina propria of mucosa-associated lymphoid tissue (MALT) (27, 28). We detected high levels of IgA in the upper airways early during acute COVID-19 that rapidly declined during convalescence, following the pattern observed for systemic IgA levels here and in other reports (29-31). This suggests that at least some IgA disseminated into the airways from the circulation. In contrast, the dynamics of IgG were different in the respiratory samples compared to plasma with airway IgG following the same kinetics as IgA, while systemic IgG were well maintained up to 8 months.
When we assessed the presence of lymphocytes in the different airway compartments during acute disease, we observed higher proportion of B cells along with high antibody levels, especially IgA, in the nasopharynx, as compared with the nostril or the endotracheal space. It has previously been shown that the majority of antibody secreting cells generated after intranasal immunization with live-attenuated vaccines in rodents may reside in the respiratory tract rather than in the spleen and bone marrow (32) and that these cells secrete IgA early after a later challenge with the vaccination pathogen (33-35). Therefore, it is possible that B cells generated during SARS-CoV-2 infection also reside locally in the airways and contribute to antibody levels in the nasopharynx. While the antibody content in NPA and ETA could be partially influenced by differences in sampling methods and sample volumes, these data suggest that antibody abundance and possibly virus neutralization via IgA differ along the respiratory tract and may be more pronounced in the nasopharynx compared to the lower airways. Altogether, our observations demonstrate that moderate and severe COVID-19 result in high levels of circulating antibodies and despite that IgG levels are well-maintained, antibody levels in the airways decline significantly after the acute phase.
Once antibody titers have waned below protective levels, the response to a secondary infection will mostly rely on the presence of resting antigen-specific memory B cells that can rapidly activate upon antigen re-exposure (13). Therefore, similar to other studies (18-20), we investigated the induction and maintenance of S-specific memory B cells. Importantly, because of the comprehensive distribution of disease severity represented in our cohort, we were able to compare the opposite ends of the COVID-19 disease spectrum by focusing on individuals with mild disease as compared with patients with moderate/severe disease who had the highest circulating IgG and IgA levels. Strikingly, despite the fact that these patients were at the opposite ends of the disease severity spectrum, they had comparable levels of S-specific memory B cells during convalescence. These appeared to be specific for epitopes on S outside of the RBD and were predominantly IgG+, rather than IgA+, which may affect the proportions of different isotypes subsequently produced in the event of antigen re-exposure.
Immunization at mucosal sites such as for example intranasal administration of live-attenuated influenza vaccines generally elicits mucosal immune responses (36). However, several studies, primarily performed with DNA and virus-like particles (VLP) vaccines, have shown that intradermal, subcutaneous and intramuscular immunization also can result in local mucosal responses that protect from mucosal challenge (37). It has been speculated that this could be due to free antigen or B cells migrating from the vaccine draining lymph nodes to the MALT (37-39). A two-dose regimen of Moderna’s mRNA-1273 vaccine administered intramuscularly and followed by intranasal and intratracheal challenge with SARS-CoV-2 in rhesus macaques has indeed shown to result in local virus neutralization in the airways (40). Antibodies in bronchoalveolar lavage and nasal swabs were elicited in a vaccine dose-dependent manner assessed after the boost vaccination (41).
Whether the systemic and/or mucosal immunity generated during natural infection is boosted by vaccination and results in a similar or enhanced magnitude of responses would be important knowledge to acquire for planning the best vaccination strategies for SARS-CoV-2 as well as for other respiratory viruses. Our results on individuals recovering from COVID-19 and subsequently receiving vaccination indicated a marked increase of both IgG and IgA levels systemically but also strikingly in the airways, which in the majority of cases exceeded the levels observed during acute disease. Notably, the antibody increase observed between prime and boost vaccination was more prominent in the airways than systemically. Recent studies on systemic antibody responses after SARS-CoV-2 vaccination in individuals who recovered from COVID-19 have shown a significant increase in antibody levels after one vaccine dose with no or only a small increase after the second dose (42-46). This suggests that one vaccine dose may be sufficient to protect these individuals from disease in case of re-infection which is important for vaccine dose management at the population level. However, our data indicate that only assessing the systemic antibody levels after vaccination is to some extent misleading as respiratory antibody levels, and likely virus neutralization, may be substantially better with a prime-boost vaccination strategy rather than with one single dose. The higher levels of airway antibodies after two vaccine doses may be explained by even a small increase in circulating antibodies after a second vaccine dose causing a substantial extravasation from the bloodstream into mucosal sites. Interestingly, two recent studies showed the presence of antibodies in the upper respiratory tract of individuals vaccinated against SARS-CoV-2 with higher levels and even neutralizing activity in small subsets of individuals who had recovered from COVID-19 before vaccination (47, 48).
In summary, here we show that COVID-19 disease severity not only determines the magnitude of systemic but also airway antibody levels with efficient generation of virus-specific memory B cells against SARS-CoV-2 also occurring upon mild disease. While plasma IgG levels were generally well detectable after acute disease in all groups, there was a significant decline in airway antibodies during convalescence. This suggests that antibodies in the airways may not be maintained at levels that prevent local virus entry upon re-exposure. However, our data indicate that the majority of infected individuals have the ability to generate anamnestic responses via the memory B cell pool and that vaccination against SARS-Cov-2 resulted in a substantial rebound of both systemic and airway antibodies in patient who recovered from COVID-19. These data indicate a positive effect of vaccination for increased virus neutralization in the airways and prospects of reduced virus spread, which further supports following the full vaccination schedule also in this population.
Methods
Study design, patient enrollment and sample collection
One hundred and forty-seven (147) PCR-confirmed SARS-CoV-2 infected patients were enrolled at the Karolinska University Hospital and Haga Outpatient Clinic (Haga Närakut), Stockholm, Sweden during March-May 2020 (acute phase) in a time that ranged from 0 to 54 days from onset of symptoms as self-reported by individual patients; and during April-September 2020 (3 months) in a time that ranged from 46 to 168 days and during November 2020 to February 2021 (8 months) continuing from the previous counts. Patients were enrolled at various settings, ranging from primary to intensive care. In order to recruit asymptomatic and mild cases, household contacts of COVID-19 patients were enrolled and screened with PCR to identify SARS-CoV-2 positive individuals. A small subset of these individuals who experienced influenza-like symptoms and were possibly exposed to SARS-Cov-2 but had a negative diagnostic PCR (PCR-) (n=9 of whom 3 were household contacts of confirmed patients with 1 experiencing fever, and 6 were included based on suspected infection with 4 experiencing fever) were sampled in the same way and included as controls alongside with 30 pre-pandemic healthy control samples (PPHC) from 2016-2018.
Respiratory failure was categorized daily according to the respiratory domain of the Sequential Organ Failure Assessment score (SOFA)(14). The modified SOFA score (mSOFA) was calculated when arterial partial pressure of oxygen (PaO2) was not available. In this case peripheral transcutaneous hemoglobin saturation (SpO2) was used instead (15). Estimation of the fraction of inspired oxygen (FiO2) based on O2 flow was calculated as per the Swedish Intensive Care register definition (49). Patients were categorized based on the peak respiratory SOFA or mSOFA value with the 4-point respiratory SOFA score being extended with additional levels to distinguish between admitted and non-admitted mild cases (both respiratory SOFA score 0) and to include fatal outcome. Ten (10) patients with fatal outcome had peak disease severity score 6 prior to death and 2 patients had scores of 4 and 5. For convenience, the resulting 7-point composite peak disease severity (PDS) was condensed into a broader classification consisting of mild (1-2), moderate (3-4), severe (5-6), and fatal (7). Demographics and additional data were collected from medical records, including clinical history and risk factors such as BMI and co-morbidities. Total burden of comorbidities was assessed using the Charlson co-morbidity index (CCI) (50) (Table 1). Additional clinical information on this patient cohort including the modulation of disease from time to study inclusion to peak severity can be found in Falck-Jones et al (16).
Blood was collected in EDTA-containing tubes from all patients except those admitted to the intensive care unit (ICU) for whom blood was pooled from heparin-coated blood gas syringes discarded in the last 12 hours. For some ICU patients, additional venous blood was also collected in EDTA tubes. Nostril swabs (NSW) and nasopharyngeal aspirates (NPA) were collected from the majority of the patients whereas endotracheal aspirates (ETA) were only collected from patients with mechanical ventilation intubated in the ICU. Admitted patients were sampled during acute disease at up to four timepoints and ICU patient material was collected up at to ten timepoints. For this study, unless otherwise stated, the measurements referring to acute disease were performed with samples collected at the time of study inclusion and when patients returned for their follow-up visits at 3 and 8 months from symptom onset. At follow-up sampling, all study individuals had been discharged (if hospitalized) from the infectious diseases ward but some individuals (<10) who recovered from severe COVID-19 were still in a hospital aftercare ward at the first follow-up sampling. All study participants were confirmed SARS-CoV-2 negative by PCR at the time of follow-up sampling, with the exception of 5 individuals who were PCR + but with high Ct values (>34).
The study was approved by the Swedish Ethical Review Authority, and performed according to the Declaration of Helsinki. Written informed consent was obtained from all patients and controls. For sedated patients, the denoted primary contact was contacted and asked about the presumed will of the patient and to give initial oral and subsequently signed written consent. When applicable, retrospective written consent was obtained from patients with non-fatal outcomes.
Enzyme-linked immunosorbent assay (ELISA)
The presence of IgG or IgA binding against the SARS-CoV-2 Nucleocapsid (N) and Spike (S) trimer or the Receptor Binding Domain (RBD) monomer (5, 6) in plasma and airway samples was assessed by enzyme-linked immunosorbent assay (ELISA). Recombinant proteins were received through the global health-vaccine accelerator platforms (GH-VAP) funded by the Bill & Melinda Gates Foundation. Briefly, 96-half well plates were coated with 50ng/well of the respective protein. Plates were incubated with a selected duplicate dilution that did not provide background noise against ovalbumin used as a negative control (data not shown) (i.e. 1:20 for plasma samples, 1:2 for NSW and NPA, and 1:5 for ETA in 5% milk/PBS buffer). Duplicate 7-point serial dilutions were initially performed for measuring plasma IgG against RBD during acute disease and after vaccination. The half maximal effective concentration (EC50) or the endpoint titer (dilution at the set OD value of 0.1) were calculated using GraphPad Prism 9. However, since for several samples with low antibody concentration (mostly from the asymptomatic/mild category) the EC50 was below the highest dilution used (of 1:20) and therefore below the limit of detection (Supplementary figure 6A), the maximal optical density (OD) at 1:20 dilution was used for most of the analyses. The relation between maximal OD and EC50 was verified in a subset of patients with high IgG and IgA against S (Supplementary figure 6B). To be able to compare pre- post-vaccination antibody levels that would, in some instances, fall below and above the lower and upper limits of detection, the endpoint titer was used instead. The relation between EC50 and endpoint titer for these samples, is shown in Supplementary figure 5. Detection was performed with mouse and goat anti-human IgG or IgA HRP-conjugated secondary antibodies (clone G18-145 from BD Biosciences and polyclonal from ThermoFisher, respectively) followed by incubation with TMB substrate (BioLegend) which was stopped with a 1M solution of sulfuric acid. Blocking with 5% milk/PBS buffer and washing with 0.1% Tween-20/PBS buffer were performed between each step. Absorbance was read at 450nm and background correction at 550nm using an ELISA reader. Data were reported as maximal absorbance i.e. OD, as stated above, and plotted using GraphPad Prism 9. All of the antibody measurements in plasma and respiratory samples from SARS-CoV-2 patients were run alongside with samples from two different control groups as described above. Interestingly, low but readily detectable IgA reactivity against S was detected in the pre-pandemic healthy controls and in the PCR-individuals (Supplementary figure 6C). After having verified the specificity and sensitivity of our ELISA assay for IgA detection with limiting sample dilutions (Supplementary figure 6D-E), we hypothesize that this might be due to cross-reactivity on the shared portions of the S protein between SARS-CoV-2 and other common cold coronaviruses. Reports have shown that cross-reactivity between coronaviruses exists (51, 52).
Flow cytometry
Staining of cells from airway samples was performed fresh. Briefly, samples were centrifuged at 400 g for 5 min at room temperature and cells were washed with sterile PBS. Mucus was removed using a 70 μm cell strainer and cells were subsequently stained with the appropriate combination of fluorescently labelled monoclonal antibodies as illustrated in Figure 5A. Staining of PBMC was performed on previously cryopreserved samples. The appropriate combination of fluorescently labelled monoclonal antibodies binding to different cell surface markers and with fluorescently labelled S and RBD proteins used as probes for antigen-specific B cells is illustrated in Figure 5C. Probes were prepared from biotinylated proteins using a 4:1 molar ratio (protein:fluorochrome-labelled streptavidin) considering the molecular weight of protein monomers and of the streptavidin only. The probes were prepared using streptavidin conjugated to PE and APC for S and with BV421 for the RBD. The gating strategy for the identification of antigen-specific memory B cells is shown in Figure 5C. Briefly, after identification of lymphocytes in single suspension, live B cells, (i.e. cells not expressing CD3/,CD14/CD16/CD56) were gated. From this gate, B cells were further isolated by expression of CD19 and CD20 and then switched memory B cells were identified as IgD-IgM-. From these, S-specific switched memory B cells were identified by binding to both S protein probes. Further characterization was then carried out by analyzing IgG expression (IgA+ switched memory B cells are assumed to mirror IgD-IgM-IgG-B cells) and fluorescently labelled RBD. Stained cells from airway samples were acquired using a BD LSRFortessa while stained PBMC were acquired using a BD FACSAria Fusion both interfaced with the BD FACSDiva Software. Results were analyzed using BD FlowJo version 10.
Statistical analyses
All statistical analyses were performed using GraphPad Prism 9. Spearman correlation was used to assess the interdependence of 2 different non-categorical parameters across individuals whereas Wilcoxon matched-pairs signed rank or Mann–Whitney U tests as appropriate, were used to assess differences or similarities for one single parameter between 2 different groups. Kruskal -Wallis with Dunn’s multiple comparisons test was used when assessing comparison between multiple groups.
Data Availability
The data that support the findings os this study are available from the corresponding author on reasonable request.
Author contributions
Experimental study design: A.C., Ka.L. and A.S-S. Clinical concept design: A.S-S., M.B., N.J., J.A., J.S. and A.F. Acquisition and sample processing: A.C., M.Y., S. F-J., S.V., B.Ö., E.Å., L.A., R.F-J., M.Ö., F.G., J.S. and M. E. Generation of data: A.C., M.Y., S. F-J., S.V., L.A. and P.C.G. Provision of custom reagents: D.P., M.M., L.C., and N.P.K. Analysis and interpretation of data: A.C., Ka.L. and A.S-S. Critical revision of the manuscript: all authors. Statistical analysis: A.C., K.L. and S.O. Ka.L. and A.S-S. contributed equally to the study.
Acknowledgments
We thank the patients and healthy volunteers who have contributed to this study. We would also like to thank medical students and hospital staff for assistance with patient sampling and collection of clinical data, the Biomedicum BSL3 core facility, Karolinska Institutet and Fredrika Hellgren for assistance with English editing. This work was supported by grants from the Swedish Research Council, the Swedish Heart-Lung Foundation, the Bill & Melinda Gates Foundation, the Knut and Alice Wallenberg Foundation through SciLifeLab and Karolinska Institutet.
Footnotes
Conflict of interest statement The authors have declared that no conflict of interest exists.
References
